Understanding of the crosstalk between normal residual hematopoietic stem cells and the leukemic niche in acute myeloid leukemia

Exp Hematol. 2021 Mar:95:23-30. doi: 10.1016/j.exphem.2021.01.004. Epub 2021 Jan 23.

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease, yet clinically most patients present with pancytopenia resulting from bone marrow failure, predisposing them to life-threatening infections and bleeding. The mechanisms by which AML mediates hematopoietic suppression is not well known. Indeed, much effort has so far been focused on how AML remodels the bone marrow niche to make it a more permissive environment, with less focus on how the remodeled niche affects normal hematopoietic cells. In this perspective, we present evidence of the key role of the bone marrow niche in suppressing hematopoietic stem cells (HSCs) during leukemic progression and provide perspectives on how future research on this topic may be exploited to provide treatments for one of the key complications of AML.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cell Communication
  • Cell Hypoxia
  • Deferoxamine / pharmacology
  • Disease Progression
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects
  • Exosomes / physiology
  • Hematopoiesis
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / drug effects
  • Homeostasis
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / pathology*
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects
  • Neoplastic Stem Cells / cytology*
  • Neoplastic Stem Cells / drug effects
  • Recurrence
  • Stem Cell Niche*
  • Tumor Cells, Cultured
  • Tumor Microenvironment*

Substances

  • Antineoplastic Agents
  • Deferoxamine